Li et al. found that CXCL13 combined with CCL18, HLA-DOB, HLA-DPB2, and TNFRSF17 is associated with better overall survival in ovarian cancer between high and low abundance immune subtypes (Li et al., 2021). This evidence concerns the gene CXCL13 and ovarian cancer.